STAAR Surgical Appoints New CFO

TL;DR

STAAR Surgical names C. Robert Muchmore as new CFO, effective immediately.

AI Summary

STAAR Surgical Company announced on June 20, 2024, that it has appointed C. Robert Muchmore as its new Chief Financial Officer, effective immediately. Muchmore previously served as the interim CFO and brings extensive financial leadership experience to the role. The company also reported on the election of directors and other executive appointments.

Why It Matters

The appointment of a permanent CFO is a significant leadership change that can impact investor confidence and the company's financial strategy.

Risk Assessment

Risk Level: medium — Changes in key executive positions like CFO can introduce uncertainty regarding future financial strategy and performance.

Key Players & Entities

• STAAR Surgical Company (company) — Registrant
• C. Robert Muchmore (person) — Appointed Chief Financial Officer
• June 20, 2024 (date) — Effective date of appointment

FAQ

Filing Documents

• staa-20240620.htm (8-K) — 69KB
• staa-ex10_1.htm (EX-10.1) — 245KB
• staa-ex10_2.htm (EX-10.2) — 11KB
• 0000950170-24-076303.txt ( ) — 488KB
• staa-20240620.xsd (EX-101.SCH) — 29KB
• staa-20240620_htm.xml (XML) — 4KB

07 Submission of Matters to a Vote of Security Holders

Item 5.07 Submission of Matters to a Vote of Security Holders. At the 2024 Annual Meeting, the Company's shareholders voted upon four proposals (the "Proposals"), as described in the 2024 Proxy Statement. The final results for the votes cast with respect to each Proposal are set forth below. As of April 22, 2024, the record date for the 2024 Annual Meeting, there were 49,131,110 outstanding shares of the Company's common stock. At the 2024 Annual Meeting, a quorum of 43,486,016 shares of the Company's common stock were represented in person or by proxy. Proposal 1: To elect seven directors to serve for a term of office expiring at the Company's 2025 Annual Meeting of Shareholders or until their successors are duly elected and qualified: Number of Shares For Withheld Broker Non-Votes Arthur C. Butcher 40,801,419 120,227 2,564,370 Stephen C. Farrell 40,744,637 177,009 2,564,370 Thomas G. Frinzi 40,366,231 555,415 2,564,370 Wei Jiang 40,745,548 176,098 2,564,370 Aimee S. Weisner 40,076,353 845,293 2,564,370 Elizabeth Yeu, MD 40,662,947 258,699 2,564,370 Lilian Zhou 40,858,097 63,549 2,564,370 Proposal 2: To approve Amendment No. 1 to the Company's Amended and Restated Omnibus Equity Incentive Plan, which increases the number of shares of Company common stock that are reserved for issuance under the plan by 2.6 million shares: Number of Shares For Against Abstain Broker Non-Votes 39,142,246 1,756,919 22,481 2,564,370 Proposal 3 : To ratify the appointment of BDO USA, P.C. as the Company's independent registered public accounting firm for the fiscal year ending December 27, 2024: Number of Shares For Against Abstain Broker Non-Votes 40,034,448 3,434,910 16,658 0 Proposal 4 : To approve, on a non-binding advisory basis, the compensation of the Company's named executive officers: Number of Shares For Against Abstain Broker Non-Votes 33,982,598 6,912,2

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. Exhibit No. Description 10.1* STAAR Surgical Company Amended and Restated Omnibus Equity Incentive Plan . 10.2* Amendment No. 1 to the STAAR Surgical Company Amended and Restated Omnibus Equity Incentive Plan . 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). ________ * Filed herewith. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. STAAR Surgical Company June 21, 2024 By: /s/ Tom Frinzi Thomas Frinzi President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR